MarketPulse

DNL151

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biogen, Denali Halt Parkinson's Drug After Phase 2b Failure

BIIB122 failed primary endpoints in Parkinson's trial despite strong safety profile. Companies discontinue idiopathic development; Denali continues variant carrier study.
BIIBDNLIclinical trial failuredrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biogen and Denali Halt BIIB122 Development After Phase 2b Parkinson's Study Fails

Biogen and Denali's LRRK2 inhibitor BIIB122 missed primary and secondary endpoints in Phase 2b Parkinson's trial. Companies discontinue development in idiopathic disease.
BIIBDNLIclinical trial failuredrug development